Free Trial

Exicure (NASDAQ:XCUR) Stock Price Down 4.5% - Here's Why

Exicure logo with Medical background

Exicure, Inc. (NASDAQ:XCUR - Get Free Report) shares fell 4.5% on Monday . The company traded as low as $9.77 and last traded at $10.04. 4,221 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 574,559 shares. The stock had previously closed at $10.51.

Exicure Trading Up 0.5%

The stock's fifty day moving average price is $11.16 and its two-hundred day moving average price is $12.62. The firm has a market capitalization of $61.73 million, a price-to-earnings ratio of -4.72 and a beta of 3.86.

Exicure (NASDAQ:XCUR - Get Free Report) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Institutional Investors Weigh In On Exicure

An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC acquired a new stake in Exicure, Inc. (NASDAQ:XCUR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned approximately 0.48% of Exicure at the end of the most recent quarter. 42.82% of the stock is currently owned by institutional investors and hedge funds.

Exicure Company Profile

(Get Free Report)

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.

Recommended Stories

Should You Invest $1,000 in Exicure Right Now?

Before you consider Exicure, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exicure wasn't on the list.

While Exicure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Defense Stocks Set to Crush the S&P This Summer
Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines